𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn’s disease

✍ Scribed by A. C. MOSS; N. FERNANDEZ-BECKER; K. JO KIM; D. CURY; A. S. CHEIFETZ

Book ID
108605362
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
67 KB
Volume
28
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term outcome of maintenance inflixi
Long-term outcome of maintenance infliximab therapy in children with Crohn's disease
✍ Jeffrey S. Hyams; Trudy Lerer; Anne Griffiths; Marian Pfefferkorn; Subra Kugatha 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 2 views

Background: Infliximab therapy has short-term benefits in children with moderate-to-severe Crohn's disease (CD). We assessed the long-term outcome of infliximab maintenance therapy in children with CD. ## Methods: We performed a multicenter cohort study of 729 pediatric patients with CD enrolled i

Mucosal healing predicts long-term outco
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease
✍ Fabian Schnitzler; Herma Fidder; Marc Ferrante; Maja Noman; Ingrid Arijs; Gert V 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 395 KB 👁 2 views

Background: Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH on the long-term outcome of IFX treatment in CD is still debated. ## Methods: We studied MH during long-term treatment with IFX in 214 CD patients. A total of 183 patients

Impact of prior irregular infliximab dos
Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn's disease
✍ Daniel J. Stein; Ashwin N. Ananthakrishnan; Mazen Issa; John B. Williams; Dawn B 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB 👁 2 views

## Background: Infliximab is efficacious in the management of moderate to severe crohn's disease (cd). there are limited data regarding performance of infliximab in patients who require reinitiation of maintenance dosing following previous irregular exposure. ## Methods: This was a retrospective,

Long-term outcome of treatment with infl
Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: A population-based study
✍ Valérie Crombé; Julia Salleron; Guillaume Savoye; Jean-Louis Dupas; Gwénola Vern 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 549 KB

Background: We examined short-and long-term benefits and safety of infliximab (IFX) in a population-based cohort of Crohn's disease (CD) patients <17 years old at diagnosis. ## Methods: The following parameters were assessed: short-and long-term efficacy of IFX, impact of drug efficacy, and mode